Red Light Holland Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Todd Michael Shapiro
- Full Time Employees
- 104
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1 Adelaide Street East Toronto ON Canada M5C 2V9
- IPO Date
- Jan 8, 2021
- CIK
- 0001836747
- Website
- redlight.co
- Similar Companies
- Business
- Red Light Holland Corp. (CSE:TRIP; OTCQB:TRUFF) engages in the production, growth, distribution and sale of functional mushrooms, mushroom home grow kits, and premium psilocybin truffles to recreational and emerging medical markets in North America, Europe and the Netherlands; core offerings include iMicrodose and Maka branded magic truffles such as Hollandia, Makanaut, Muskoka, Mexicana, Atlantis, Double Vision, Old Dutch and Utopia varieties; Happy Caps mushroom home grow kits in shiitake, oyster and lion's mane; functional mushroom gummies; MiniChamp home cultivation packages; Mistercap’s wellness products; and related items encompassing cannabidiol products, cannabis seeds, headshop goods, growshop items, cannabis-infused baked goods, Wisdom Truffle figurines and iMicroapp tele-counseling platform. The Toronto-headquartered company, founded in 1982, operates key subsidiaries including wholly-owned Happy Caps Mushroom Farms, SR Wholesale B.V., RLH Netherlands B.V., MiniChamp B.V., AEM (gourmet mushrooms) and Wellness World entities, with production facilities in the Netherlands' Horst region, Canadian farms in New Brunswick, Ontario and Nova Scotia, and partnerships extending to the United States; it serves brick-and-mortar SmartShops, online platforms, major retailers like Costco Canada (82 locations for Happy Caps Mega Block kits), Albertsons/Safeway, Real Canadian Superstore pilots and over 270 Canadian stores via distributors such as Van Noorts. Recent developments encompass full acquisition of Happy Caps minority interest in April 2024; strategic partnership with Trailbridge Mushroom Farms in Oregon for U.S. West Coast distribution in September 2024; expanded Costco Canada reorders totaling over 33,000 Mega Block kits and commitments for 20,000 more in 2025; launch of Health Canada-approved Fun(ctional) Mushroom Gummies (NPN #80137179) on Amazon with stability testing cleared; R&D advancements with FDA-compliant/DEA-registered Irvine Labs including 5kg psilocybin truffle shipments in 2025 for microdosing capsules, potency testing and shelf-life processes; collaboration with Arizona State University on the Psychedelic Genome Project; appointment of Dr. Robin Carhart-Harris as Scientific Advisor; prior partnership with Professor David Nutt and Drug Science for microdosing research; Bitcoin treasury strategy allocating up to $2 million; operational streamlining via sale of Oss retail store, suspension of AEM New Brunswick shiitake production by December 2025 and advanced sale talks for AEM Ontario Peterborough farmland rights at $2.5-2.6 million; and active pursuit of research-driven M&A opportunities as of Q2 2026 results reported November 2025.
Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp
Red Light Holland Announces New Filament Health PEX010 European Research Shipment
Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France
Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinical Alzheimer's Markers
Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechanism Research
Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders
Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property
Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions
Red Light Holland Announces Intention to Rebrand
Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution
Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement
Red Light Holland Announces Filament Health Shareholder Approval of Acquisition
Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate
Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments